Progress in radioligand therapy with ¹⁷⁷Lu-PSMA for the treatment of metastatic castration-resistant prostate cancer

Prostate cancer is one of the most common malignancies worldwide. Many advances have been made over the past years, but the treatment of metastatic prostate cancer remains challenging. In many cases, existing therapies have become ineffective for controlling tumor progression. Thus, new approaches are urgently needed. Radioligand therapy with ¹⁷⁷Lu-Prostate specific membrane antigen (PSMA) is an innovative and effective therapy for patients with castration-resistant metastatic prostate cancer. PSMA is expected to be a standard regimen for prostate cancer as it is well tolerated by patients and has high potential for improving overall survival.